Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on discovering, developing, and commercializing novel orally administered antivirals. Its lead program is the combination regimen of bemnifosbuvir and ruzasvir for hepatitis C virus (HCV) treatment, currently in Phase 3 trials (C-BEYOND and C-FORWARD). It is also developing AT-587, a potential first direct-acting antiviral for chronic hepatitis E virus (HEV) infection, targeting immunocompromised patients, with a Phase 1 study anticipated in mid-2026.
expected 2026-11-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001193125-26-094159 | EDGAR | 101K words |
| 2025-03-06 | 2024-12-31 | 0000950170-25-034808 | EDGAR | 96K words |
| 2024-02-28 | 2023-12-31 | 0000950170-24-022226 | EDGAR | 105K words |
| 2023-02-28 | 2022-12-31 | 0000950170-23-005186 | EDGAR | 114K words |
| 2022-02-28 | 2021-12-31 | 0001564590-22-007672 | EDGAR | — |
| 2021-03-30 | 2020-12-31 | 0001564590-21-016724 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-12 | 2026-06-30 | 0001193125-26-347021 | EDGAR | 67K words |
| 2025-11-12 | 2025-09-30 | 0001193125-25-277815 | EDGAR | 67K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105123 | EDGAR | 66K words |
| 2025-05-12 | 2025-03-31 | 0000950170-25-069367 | EDGAR | 64K words |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123447 | EDGAR | 64K words |
| 2024-08-07 | 2024-06-30 | 0000950170-24-092914 | EDGAR | 69K words |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059699 | EDGAR | 67K words |
| 2023-11-08 | 2023-09-30 | 0000950170-23-061213 | EDGAR | 71K words |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039920 | EDGAR | 70K words |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018869 | EDGAR | 67K words |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022699 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0000950170-22-015570 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-12 | 0001193125-26-346888 | EDGAR | 3K words |
| 2026-03-05 | 0001193125-26-093961 | EDGAR | 4K words |
| 2026-01-08 | 0001193125-26-007081 | EDGAR | 2K words |
| 2025-11-12 | 0001193125-25-277627 | EDGAR | 4K words |
| 2025-08-07 | 0001193125-25-175433 | EDGAR | 3K words |
| 2025-06-20 | 0001193125-25-143750 | EDGAR | 1K words |
| 2025-05-12 | 0001193125-25-117809 | EDGAR | 3K words |
| 2025-04-17 | 0001193125-25-083523 | EDGAR | 1K words |
| 2025-04-01 | 0001193125-25-069932 | EDGAR | 1K words |
| 2025-03-24 | 0001193125-25-060794 | EDGAR | 1K words |
71 total filings indexed. 43 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001593899 |
| Ticker | AVIR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | MA |
| Website | https://www.ateapharma.com |
| Listed | 2020-10-30 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/AVIR (~200 tokens, structured JSON with cryptographic provenance)